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Abstract
Background
Multiple sclerosis (MS) is a multifactorial autoimmune disease of the central nervous system
with a heterogeneous and unpredictable course. To date there are no prognostic biomark-
ers even if they would be extremely useful for early patient intervention with personalized
therapies. In this context, the analysis of inter-individual differences in cerebrospinal fluid
(CSF) proteome may lead to the discovery of biological markers that are able to distinguish
the various clinical forms at diagnosis.
Methods
To this aim, a two dimensional electrophoresis (2-DE) study was carried out on individual
CSF samples from 24 untreated women who underwent lumbar puncture (LP) for suspected
MS. The patients were clinically monitored for 5 years and then classified according to the
degree of disease aggressiveness and the disease-modifying therapies prescribed during
follow up.
Results
The hierarchical cluster analysis of 2-DE dataset revealed three protein spots which were
identified by means of mass spectrometry as Apolipoprotein E (ApoE) and two isoforms of
vitamin D binding protein (DBP). These three protein spots enabled us to subdivide the pa-
tients into subgroups correlated with clinical classification (MS aggressive forms identifica-
tion: 80%). In particular, we observed an opposite trend of values for the two protein spots
PLOS ONE | DOI:10.1371/journal.pone.0129291 June 5, 2015 1 / 24
OPEN ACCESS
Citation: Perga S, Giuliano Albo A, Lis K, Minari N,
Falvo S, Marnetto F, et al. (2015) Vitamin D Binding
Protein Isoforms and Apolipoprotein E in
Cerebrospinal Fluid as Prognostic Biomarkers of
Multiple Sclerosis. PLoS ONE 10(6): e0129291.
doi:10.1371/journal.pone.0129291
Academic Editor: Heinz Wiendl, University of
Münster, GERMANY
Received: December 24, 2014
Accepted: May 6, 2015
Published: June 5, 2015
Copyright: © 2015 Perga et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any
medium, provided the original author and source are
credited.
Data Availability Statement: All relevant data are
within the paper and its Supporting Information files.
Funding: This work was supported by the
Fondazione Italiana Sclerosi Multipla (FISM - Grant
number 2007/R/1). The sponsor had no role in the
design and conduct of the study, in the collection,
analysis, and interpretation of the data, or in the
preparation of the manuscript. ABLE Biosciences and
LIMA provided support in the form of salaries for
authors AGA, KL, NM, SF, RR, and DC, but did not
have any additional role in the study design, data
collection and analysis, decision to publish, or
corresponding to different DBP isoforms suggesting a role of a post-translational modifica-
tion rather than the total protein content in patient categorization.
Conclusions
These findings proved to be very interesting and innovative and may be developed as new
candidate prognostic biomarkers of MS aggressiveness, if confirmed.
Introduction
Multiple sclerosis (MS) is a complex pathology, presumably of autoimmune origin, of the cen-
tral nervous system (CNS). Its clinical course is unpredictable and varies greatly from patient
to patient, ranging from very aggressive to benign forms, stationary for decades even if not
treated with specific therapies. Unfortunately, to date there are no biological markers that are
capable of distinguishing the various clinical forms at diagnosis. Biomarkers of this kind are es-
sential for choosing the most suitable and timely treatment. In fact, benign patients are clinical-
ly stable without treatment, while an early and effective therapy for aggressive-relapsing forms
could significantly affect the course of the disease, thus causing less permanent damage and
leading to better quality of life [1].
CSF represents a unique repository of substances secreted by the CNS, demonstrating the
presence and the progression of neurological diseases. Therefore, the study of inter-individual
differences in the CSF proteome may lead to the discovery of innovative markers that would be
useful for prognosis [2].
Although proteomic-based approaches are excellent techniques for biomarker investigation,
they have not yet given reliable results in CSF biomarker studies [3] due to technique variability
and pre-analytical factors such as sample collection, patient heterogeneity and difficulties in
defining and selecting patients and control groups [4, 5]. Moreover, one of the main problems
observed when carrying out CSF proteomic studies is the small amount of CSF obtained from
each subject. In fact, most of the CSF proteomic data were obtained from “pooled” samples [6,
7, 8, 9] and not from single-patient CSF analysis [10, 11, 12, 13]: CSF pooling may minimize
the potential inter-individual differences of CSF protein content among single patients which
are not associated with the underlying disease. These variations in individual CSF protein con-
tent may be responsible for the extremely controversial results of previous CSF proteome stud-
ies in neurological diseases even when using the same technical approach. On the other hand,
CSF pooling may also hinder the detection of markers of various subtypes of neurological dis-
eases linked to potentially different pathomechanisms [10].
Therefore, in order to overcome these artefacts, a two dimensional electrophoresis (2-DE)
study with all the procedures and methodological steps standardized as described by Teunissen
et al, 2009 [4] was carried out.
Furthemore, we analyzed the single patient CSF proteome(s) by performing at least three
technical replicates thanks to the availability of a large amount of CSF from each patient, ob-
tained by means of a new drawing procedure developed by neurologists at the Regional Referral
Multiple Sclerosis Centre (CReSM) [14].
In order to avoid bias related to treatment [5] and gender, we enrolled a group of 24 untreat-
ed women undergoing lumbar puncture (LP) for suspected MS and we then monitored them
for 5 years.
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We decided not to include a control group for various reasons: the difficulty in obtaining
CSF samples from healthy controls and the confusion concerning the recently-defined selec-
tion criteria for adequate neurological controls [5]. The aim of this study was to identify bio-
markers with prognostic rather than diagnostic value.
By means of the hierarchical cluster analysis of proteomic data and correlation with clinical
parameters, we identified potential biomarkers that were capable of stratifying MS patients ac-
cording to the clinical aggressiveness of the disease.
Materials and Methods
Standard protocol approval, registration and patient consent
The study was approved by the Piedmont and San Luigi Hospital Ethics Committee and all the
partecipants signed a written informed consent.
Patients and CSF collection
The 24 cases enrolled in the study were selected according to the following clinical laboratory
inclusion criteria: a) female gender; b) clinical signs or symptoms suggesting MS [15]; c) never
treated with DMT; d) subjected to LP between January 2008 and April 2009; e) availability of
more than 15 ml of CSF.
The LP was performed by neurologists at the Neurology Unit 2—CReSM of the San Luigi
University Hospital, where patients were clinically monitored for the following 5 years. CSF
samples were collected during the remitting phase and from patients who were not
undergoing therapy.
The mean age at the the moment of the LP was 36.5 ± 10.8 years (SD, standard deviation),
ranging from 17 to 61 years of age. Detailed clinical patient information is summarized in
Table 1. Follow-up data of patient MS 41 are not available since this patient was lost to follow-
up. The LP was performed in the L4-L5 intervertebral space following a procedure that causes
very low percentages of post-LP headache and provides up to 20 ml of CSF [14]. The LP was
performed using a 25 gauge Sprotte needle. This procedure takes longer than the traditional LP
performed with 20 or 22 gauge needles because it requires an introducer and the aspiration of
the CSF, but it reduces the risk of post-dural puncture headache to less than 2% and allows the
collection of 20 ml of CSF.
CSF collection, storage and bio-banking were performed according to the consensus proto-
col described by C. Teunissen et al., [4]. CSF was collected in polypropylene tubes. Protease in-
hibitors (Leupeptin, Cat. No. L2884; Pepstatin A, Cat. No. P4265; Aprotinin, Cat. No. A4529,
all bought from Sigma Aldrich, Missouri, USA) were added and CSF was centrifuged at 1,000 x
g at 4°C for 10 min in order to remove cells and insoluble material and finally stored at –80°C
until analysis. CSF samples were only included in the 2-DE study if more than 15 ml of CSF
were available and if they contained less than 5 erythrocytes per μl. Detailed CSF biochemical
data are reported in Table 2.
CSF sample preparation
All phases related to sample preparation, 2-DE and statistical analysis were performed by re-
searchers blindly as regards the clinical data-set in order to avoid bias in the results.
Each CSF sample was concentrated up to 20-fold and desalted by means of Ultrafree MC
cartridges with a 5 kDa cut-off (Millipore, Bedford, USA). Following this step, the protein con-
centration was determined with the Bradford method using bovine serum albumin as
protein standard.
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Two-dimensional electrophoresis
2-DE experiments were carried out in triplicates according to Robotti et al. [16] and performed
after conclusion of the CSF sample collection. An amount of 100 μg total proteins from each
sample was loaded for each 2-DE gel.
Image analysis
The gels were stained with Ruby Sypro (Invitrogen, Eugene, USA) according to the manufac-
turer’s instructions and scanned with a ProXPRESS 2D CCD camera (Perkin Elmer, Waltham,
USA). Image analysis was performed with the Image Master 2D Platinum 5.0 software package
(GE Healthcare, Uppsala, Sweden). Spot detection and gel matching were carried out
Table 1. Clinical data of patients enrolled in the study.
Patients Gender EDSS at
LP time
ΔEDSS at 5
years fu
Relapse N°
at 5 years fu
RR at 5
years fu
DMT at 2
years fu
DMT at 5
years fu
Clinical
class. at 2
years fu
Clinical
class. at 5
years fu
Final
diagnosis
MS25 F 6 0 0 0 none none PPMS PPMS PPMS
MS26 F 1 1* 1* 0.2* I death M death RRMS
MS27 F 1 2.5 4 0.8 II II H H RRMS
MS28 F 1.5 5 3 0.6 I II M H RRMS
MS29 F 6 0 3 0.6 II II H H RRMS
MS30 F 1 0 1 0.2 I I M M RRMS
MS31 F 0 1 3 0.6 none I L M RRMS
MS32 F 1.5 0,5 1 0.2 I I M M RRMS
MS33 F 0 1 2 0.4 I I M M RRMS
MS34 F 0 0 0 0 none none L L RRMS
MS35 F 1 1 2 0.4 I I M M RRMS
MS36 F 1 0 0 0 none none L L RRMS
MS37 F 0 1 0 0 I I M M RRMS
MS38 F 1 0 2 0.4 I I M M RRMS
MS39 F 1.5 0 0 0 none none L (B) L (B) Benign MS
MS40 F 1 0 1 0 none none L (B) L (B) Benign MS
MS41 F 3.5 0** lost lost *** lost lost lost RRMS**
MS42 F 0 1 1 0.2 I I M M RRMS
MS43 F 4 0 ? ? I I M M RRMS
MS44 F 2 0 3 0.6 II II H H RRMS
MS45 F 0 0 0 0 none none L L RRMS
MS46 F 0 0 2 0.4 I I M M RRMS
MS47 F 2 0 4 0.8 II II H H RRMS
MS48 F no MS no MS no MS no MS no MS no MS no MS no MS Somatoform
disorder
F = female; LP = lumbar puncture time; EDSS = Expanded Disability Status Scale; ΔEDSS = difference between EDSS assessment at the diagnosis after
5 years of follow-up; fu = follow-up; RR = relapse-rate; DMT = disease-modifying treatments, indicated as: first line (I), second line (II) pharmacological
treatments or absence of therapy (none). Clinical class. = clinical classification according: H (high) = highly aggressive disease, second-line therapy; M
(moderate) = moderately aggressive disease, first-line therapy; L (low) = mildly aggressive disease; L (B) = “benign” disease, characterized by absence or
progression no therapy. PPMS = primary progress multiple sclerosis; RRMS = relapsing remitting multiple sclerosis
* data available at 2-year follow-up
** data available at 1-year follow-up
*** no therapy prescribed at diagnosis.
doi:10.1371/journal.pone.0129291.t001
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automatically and checked manually. For the quantitative analysis, the volume (i.e. the area of
the spots multiplied by intensity) of each spot was normalized to the total volume of matched
spots in the gel (%Vol). In order to visualize phosphorylated proteins, the gels were stained
with Pro-Q Diamond (Invitrogen, Eugene, OR) [17] prior to incubation with Sypro.
Data elaboration: hierarchical clustering, statistical and discriminant
analysis
Hierarchical clustering and linear discriminant analysis were performed with StatisticXL Ver-
sion 1.x software (CustomCD, http://www.statisticxl.com). The unweighted pair group method
with arithmetic mean (UPGMA) was selected as the clustering method and Euclidean distance
was selected as the similarity measure. The statistical analysis (MannWhitney’s test, threshold:
P<0.05, performed using GraphPad Instat version 3.00) and fold-change criteria (threshold:
>1.5) were applied in order to detect spots which varied in their %Vol in the identified clusters.
MannWhitney’s test was also applied for evaluating the differences between cluster A and B re-
lated to age and total protein and albumin concentration in either CSF or serum (Fig 1A and
1B and Table 2), Ig Index or cell number. Predictive values were derived from the observed
prevalence of the various forms of the disease. The differences in proportion of the various ag-
gressive forms of MS across the clusters were assessed by χ2 test.
Table 2. Biochemical features of CSF in individual patients enrolled in the study.
Patients CSF protein
(mg/dl)
Serum protein
(mg/dl)
CSF IgG (mg/
dl)
Serum IgG (mg/
dl)
CSF Albumin
(mg/dl)
Oligoclonal
Bands
IgG
Index
Cells/
ml
MS 25 20 683 0.585 443.7 8.7 - 0.44 3
MS 26 34 1190 3.52 345.6 15.7 + 0.65 5
MS 27 36 1467 11.5 378.5 14.4 + 2.1 28
MS 28 72 909 7.32 382.7 x + 0.5 20
MS 29 30 1562 5.08 494.5 16.9 + 1 16
MS 30 22 1475 3.72 436.4 9.3 + 1.18 20
MS 31 35 1170 18.7 548.4 13.4 + 6.5 45
MS 32 36 634 3.38 360.1 13.7 + 1.4 8
MS 33 35 790 6.21 443.8 24.1 + 1.4 38
MS 34 33 920 7.22 448.6 23.6 + 1.5 16
MS 35 25 892 2.75 437.8 21 + 0.6 3
MS 36 38 1002 7.67 325.8 17.4 + 1.4 5
MS 37 29 1072 3.39 338.7 19.2 + 0.6 3
MS 38 21 988 3.32 362.2 12.6 + 0.1 8
MS 39 59 903 4.96 349 39.1 + 0.5 3
MS 40 49 1133 3.03 522.7 22.2 - 0.63 3
MS 41 36 1241 3.51 297.5 23.5 - 0.4 3
MS 42 32 1023 1.62 397.8 23.5 - 0.3 2
MS 43 46 1463 6.74 383.8 27.6 + 0.6 8
MS 44 40 1310 2.27 372.3 33.5 + 0.2 2
MS 45 43 1052 3.66 402 33.1 - 0.42 2
MS 46 35 955 4.7 346.1 20.7 + 0.82 8
MS 47 29 1103 4.39 432.7 17.3 + 1 6
MS 48 31 644 1.61 334.5 23.6 - 0.4 2
doi:10.1371/journal.pone.0129291.t002
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Protein identification by mass spectrometry
Protein spots were excised from the 2-DE gels and analyzed by means of the HP 1100 nanoLC
system together with a XCT-Plus nanospray-ion trap mass spectrometer (Agilent) as previous-
ly described [18]. Mass spectrometry data were fed into the Mascot search algorithm in order
to search against the NCBI non-redundant database NCBI number 20150213 (http://www.
Matrixscience.com). Hits with a probability-based Mowse score higher than 47 were consid-
ered significant (p< 0.05).
2-DEWestern blotting
2-DE gels were transferred to nitrocellulose membranes with the semidry transfer method. The
membranes, saturated with 5% BSA, were incubated over-night with specific primary antibod-
ies: anti-ApoE (sc-13521, Santa Cruz Biotechnology, Heidelberg, Germany) used at 1:5000 di-
lution and anti-DBP (SAB2501100) Sigma Aldrich, Missouri, USA) used at 1:500 dilution,
followed by specific HRP-conjugated secondary antibodies. The membranes were developed
with an ECLWestern Blotting substrate kit (Thermo Scientific, Rockford, IL USA).
Definition of the clinical criteria for classification
Clinical classification was performed by the neurologists of CReSM according to the degree of
disease aggressiveness, based on the type of disease-modifying treatment (DMT) used or pro-
posed at the end of the 5-year follow-up. The neurologists were not aware of the aim of the
study and were not involved in any phase of data elaboration. An intermediate clinical evalua-
tion was carried out 2 years later. The DMT was chosen by the neurologists according to the in-
dications of the European Medicine Agency (EMA) (http://www.ema.europa.eu/ema/) and the
Italian Medicine Agency (AIFA) (http://www.agenziafarmaco.gov.it/en). DMT are subdivided
in first and second-line drugs. First-line treatments include Interferon β (IFNβ) and Glatiramer
acetate while second-line treatments include Natalizumab (NAT) and Finglimod (FIN). Sec-
ond-line drugs can be used for non-responders to first-line drugs, when they have at least two
relapses within one year of treatment. Patients may also be prescribed NAT or FIN as first
DMT if they have an aggressive disease characterized by two relapses in the previous year and
Expanded Disability Status Scale (EDSS)2 [19]. All the drugs are available for all patients
without restriction since the Italian National Health System offers all Italian citizens therapeu-
tic options which are free for chronic and oncological diseases.
According to the above-mentioned criteria, highly (H), moderately (M) and “benign” or
scarcely (L) aggressive forms were observed (Table 1). The H group included patients treated
with second-line therapies (NAT) as first treatment or changed from a first-line treatment dur-
ing the 5-year follow-up; the M group included patients treated with first-line therapies with
one or less relapses per year; the L group consisted of untreated patients due to no or low dis-
ease activity and no progression of disability (Table 1). This group also included the “benign”
forms (L-B) defined as patients with a stable disease over a 10-year period without any
pharmacological therapy.
Fig 1. Biochemical features of CSF of patients in clusters A and Cluster B. Column bar graphs representing the mean value ± SD of total protein,
albumin and Immunoglobulin (IgG) content in the CSF (A) and serum (B), Ig Index (C) and number of cells/μl in the CSF (D) of samples from patients included
in cluster A and B. The statistical analysis showed that there are no statistical differences between clusters A and B for the analysed parameters. (E) The
hierarchical cluster analysis based on spot representing IgG proteins highlighted patients MS25, MS31 and MS27 as outliers.
doi:10.1371/journal.pone.0129291.g001
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Data Availability
Raw data regarding CSF 2-DE maps, spots %Vol of each replicate used for variability testing,
spots %Vol used for final cluster analysis, Mass spectrometry protein identification and CSF
2-DE maps are available as Supporting Information files (S1 Dataset, S2 Dataset, S3 Dataset
and S1 Images respectively).
Results
Pre-analytical phase: CSF collection, preparation and 2-DE analysis
2-DE technology was used for studying the proteome pattern of the CSF samples collected
from a population of untreated women with MS. 2-DE was carried out on the whole protein
samples without depleting high-abundant proteins such as albumin. We chose this strategy
considering that albumin removal may lead to the loss of the potential biomarkers it carries
and that CSF does not contain such a large amount of high-abundant protein, such as blood/
plasma [20]. The extraction protocol used provided approx. 900 μg ± 350 (SD) proteins from
approx. 4 ml of each CSF sample, which enabled us to perform at least three technical 2-DE
map replicates for each patient. The average total protein concentration was 24.2 mg/dl ± 9,5
(SD) (range 11 to 43 mg/dl). A mean of 438 ± 94 SD spots were detected per single 2-DE map
and approx. 80% of all the detected spots were matched with the respective technical replicates.
The variability of technical replicates among matched spots was evaluated and expressed as a
mean percentage SD (%SD): this value ranged from 17% to 32%. Replicates showing a variabili-
ty higher than 32% were excluded from the analysis and new replicates were produced: the two
best replicates were kept and used for the final analysis. All the selected 2-DE gels were includ-
ed in a single class in the workspace of the Image Master software package and matched with
the selected reference gel. The matching rate of each map versus the selected reference gel ran-
ged from 65% to 97%.
Cluster analysis and clinical correlation
The results were expressed as the mean value of %Vol ± SD calculated considering the best two
replicates among the 2-DE maps performed in triplicates. A clustering analysis, performed as
described in Materials and Methods, was carried out selecting the most representative spots
present in the entire gel population (239 spots). Two main clusters (A and B) and five outliers
were identified with this approach (Fig 2A).
Clusters A and B did not differ by patient age, total protein and albumin concentration in ei-
ther CSF or serum, Ig Index or CSF cell number (Fig 1A–1D, and Table 2).
Among the five outliers, MS27, MS31 and MS25 represented the patients who had the high-
est (MS27 and MS31) and the lowest (MS25) amount of CSF immunoglobulin G (IgG), respec-
tively, while patients MS41 and MS45 showed negative oligoclonal bands (OCBs). The diverse
amount of IgG in the three patients was also confirmed by the different %Vol of the spots cor-
responding to light chains of IgG in the 2-DE maps (Fig 1E). Patient MS25, who is the oldest
woman participating in the study, has recently been declared as Primary Progressive MS
(PPMS).
In order to determine the most relevant spots for distinguishing between clusters A and B, a
MannWhitney’s test (threshold: P<0.05, performed using GraphPad Instat version 3.00 soft-
ware) on %Vol values was applied (Table 3).
By using this statistical approach, a panel of 12 differently expressed spots (Fig 2B) were
found which were subsequently identified with mass spectrometry analysis (Table 4).
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Among these, three spots showing the widest inter-individual %Vol variation within the
analysed samples were selected, namely spots ID288, ID289 and ID469 (0.00–0.44; 0.06–0.33;
0.01–0.54 respectively) (Fig 3). They were identified as follows: spot ID469 as ApoE; spots
ID288 and ID289 as two isoforms of DBP (Table 4). We therefore focused on these two pro-
teins and the three corresponding spots in order to perform a further cluster analyses.
Two spot-based (ID288, 289) cluster analysis (DBP isoforms). The combination of spot
ID289 and ID288%Vol values in the following two linear functions, obtained by means of line-
ar discriminant analysis
f1 ¼ 33:813  ð%Vol spot ID288Þ þ 48:942  ð%Vol spot ID289Þ  7:155
f2 ¼ 103:508  ð%Vol spot ID288Þ þ 42:871  ð%Vol spot ID289Þ  15:248
enabled us to divide the entire population into two groups (Fig 4A). This result, also repre-
sented by a dendrogram obtained by carrying out a cluster analysis on these two spots, led to
the identification of two new clusters (G and Z) and an outlier (MS48) (Fig 4B).
The column bar graphs reported in Fig 4C show an inverse trend of the average %Vol values
of spot ID288 and ID289 in clusters G and Z.
An opposite trend of the two DBP isoforms in the entire population had already been
highlighted by the content of the corresponding two spots in single CSF samples (Fig 3A and
3B). In fact, most patients with the highest values of spot ID288 showed the lowest values of
spot ID289 and vice versa. The inverse distribution of the %Vol of spots ID288 and ID289 in
the sample population was also confirmed by the Spearman correlation test (r = -0.49,
Fig 2. Cluster analysis based on 2-DE data from CSF gels and differently expressed spots. (A)
Hierarchical cluster analysis based on the %Vol values of the 239 most representative spots of the analysed
gel population. For each spot, the mean value of %Vol was calculated considering the best two replicates
(average SD lower than 30%) among 2-DEmaps performed in triplicates. Two main clusters (A and B) and
five outliers were identified. (B) A representative 2-DEmap of CSF: differently expressed spots between
cluster A and B are outlined in black.
doi:10.1371/journal.pone.0129291.g002
Table 3. Statistical analysis of spots differently expressed between cluster A and cluster B.
Spot ID Cluster A (%Vol) Cluster B (%Vol) P Value (<0.05) Fold-change§ (>1.5)
70 0.045 ± 0.008 0.034 ± 0.008 * ~
72 0.040 ± 0.008 0.024 ± 0.014 ** #1.7
97 0.125 ± 0.035 0.210 ± 0.057 ** "1.7
98 0.033 ± 0.003 0.046 ± 0.011 * ~
99 0.022 ± 0.007 0.015 ± 0.005 * # 1.5
101 0.053 ± 0.012 0.041 ± 0.006 * ~
102 0.108 ± 0.023 0.082 ± 0.013 * ~
117 0.062 ± 0.015 0.048 ± 0.014 * ~
227 0.034 ± 0.009 0.026 ± 0.005 * ~
288 0.224 ± 0.150 0.139 ± 0.099 NS #1.6
289 0.121 ± 0.025 0.214 ± 0.082 * "1.7
469 0.123 ± 0.048 0.190 ± 0.0944 NS "1.5
§ In the fold change column cluster B is compared to cluster A. Values are expressed as the mean of Vol% ± SD of spots detected in 2-DE map from
each patient included in cluster A or B.
NS = not statistical significant (Mann Whitney test).
doi:10.1371/journal.pone.0129291.t003
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p = 0.015, Fig 4D) which showed that the spot values in each patient were inversely correlated
with one another.
Cluster analysis was therefore correlated with the clinical classification (Table 5) according
to the disease-modifying treatment at 2- and 5-year follow-ups (Tables 1 and 5).
Notably, the two-spot based cluster analysis showed that most patients suffering from ag-
gressive disease (H category) were clustered together. In fact, cluster Z included all 4 patients
belonging to the H subgroup (100%) after the 2-year follow-up, 4 out of 5 patients (80%) be-
longing to that subgroup after the 5-year follow-up (Tables 5 and 6) and patient MS25 diag-
nosed with PPMS.
On the other hand, Cluster G included 70% of patients with moderate (M) forms at the
5-year follow-up and all patients characterized by very slow disease progression (L), also in-
cluding the two patients defined as “benign” (L-B) MS (MS39 and MS40) (see Material and
Methods) (Tables 5 and 6). Interestingly, the final diagnosis of the outlier (MS48) was not MS
but somatoform disorder.
Three spot-based (ID288, 289, 469) cluster analysis (DBP isoforms and ApoE). A fur-
ther cluster analysis was performed which also included spot ID469 in order to assess the ApoE
contribution (spot ID469) to patient stratification obtained considering the DBP isoforms
(spots ID288 and ID289).
The three spot-based clustering highlighted 3 subsets of patients (B1, C1, D1) (Fig 5A) and
singled out subject MS25 as an outlier: this patient was later diagnosed as having a PPMS form.
Spots ID469 and ID289 showed the highest mean %Vol in cluster B1 and the lowest mean
%Vol in C1 (Fig 5B). On the contrary, spot ID288 once again showed an opposite trend com-
pared to spot ID289 with the highest %Vol average in cluster C1 and the lowest %Vol average
in B1 (Fig 5B).
Considering the clinical evaluations, cluster B1 and D1 were very similar to cluster Z and G
respectively, while the addition of ApoE to patient stratification enabled us to isolate a small
group of patients included in cluster C1 (Table 5).
Table 4. Mass spectrometry identification of protein differently expressed between cluster A and B.
Spot
ID
LC-MS/MS
identification
Accession
number (gi)
Peptide
number
Aminoacidic
coverage (%)
Sequence
coverage
Theoretical MW
(KDa)/pI
Mascot
score
70 Complement B factor 291922 10 18 51–696 85.4/6.5 206
72 Complement B factor 291922 12 18 183–707 85.4/6.5 221
97 Gelsolin isoform
precursor
4504165 20 36 33–748 85.6/5.9 416
98 Gelsolin isoform
precursor
4504165 6 10 148–738 85.6/5.9 117
99 Afamin precursor 4501987 6 11 89–453 69/5.6 62
101 Serum transferrin 110590597 5 10 25–508 74.6/6.6 158
102 Serum transferrin 110590597 19 29 25–674 74.6/6.6 342
117 Alpha 1-b-
glycoprotein
69990 3 6 86–415 51.9/5.6 77
227 Albumin fragment 28592 3 5 427–581 69.3/6 54
288 Vitamin D-binding
protein
181482 12 29 52–440 53.0/5.4 277
289 Vitamin D-binding
protein
181482 20 56 52–471 52.9/5.4 494
469 Apolipoprotein E 178853 18 63 20–317 36.1/5.8 424
doi:10.1371/journal.pone.0129291.t004
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This cluster contained 4 patients. Follow-up data were available for 3 of them while one pa-
tient (MS41), lacking follow-up data, had a 13-year disease duration before LP and she was dis-
charged without undergoing any treatment. Two patients (MS39 and MS40) included in the L
category were the only participants with “benign”MS (Tables 1 and 5) who had a long disease
duration (33 and 19 years, respectively), EDSS at the LP time of 1.5 and 1.0 respectively and a
ΔEDSS after 5 years equal to zero; they had never taken any DMT. As already mentioned, the
fourth subject (MS 48) was suffering from a somatoform disorder.
On the other hand, similar to cluster Z, cluster B1 included 4 out of 5 patients (80%) with
highly aggressive disease (H category) and only 1 out of 10 (10%) patients with a moderate (M)
form (Tables 5 and 6). It also included all the patients with an aggressive form after the 2-year
follow-up.
The largest cluster D1 was very similar to cluster G and contained 13 patients: 9 out of 10
patients (90%) on a first-line therapy with a moderately aggressive form (M category) of MS, 3
out of 5 patients (60%) with a mildly aggressive disease i)(L) and one patient (MS28) who
switched from the M to the H category after 2 years (Tables 5 and 6). Patients with the most ag-
gressive form of MS (cluster B1) showed the lowest amount of spot ID288 and the highest
amount of spot ID289. An opposite trend was observed in the “benign” form of MS (cluster
C1, Fig 5).
Assuming that the sampling is representative of the prevalence of the various forms of the
disease in the population, the probabilities of being classified as H, M or L are reported in
Table 7. According to these data, both clusterization at two and three spots (Figs 4B and 5A)
showed a statistically significant different distribution of the various forms in the subgroups
(p = 0.016 and p = 0.001 respectively, at the two-year follow-up; p = 0.027 and p = 0.002 respec-
tively, at the five-year follow up) (Table 7). However, the three spot-based clustering at the
five-year follow-up better identified patients who had developed aggressive and benign forms
of MS.
2-DE western blotting validation of the different distribution of ApoE and
DBP isoforms in aggressive and benign MS patients
2-DEWestern blotting on pooled samples with specific antibodies against ApoE and DBP con-
firmed the %Vol difference between clusters C1 and B1 (Fig 6A and 6B), which mainly includ-
ed benign and aggressive forms, respectively.
Phospho-proteomic analyses of DBP isoforms
Post-translational modification (PTM) of DBP isoforms, i.e. phosphorylation, has already been
described and a possible role in MS has been suggested [21]. In order to verify whether phos-
phorylation could be responsible for the two DBP isoforms, we carried out preliminary phos-
pho-proteomic experiments using the ProQ Diamond staining technology and comparing the
pooled CSF of patients in cluster B1 with that of cluster C1. The ratio between ProQ and Sypro
intensity signal (D/S) of spots ID288 and ID289 was lower than 0.08, meaning that these pro-
teins are not phosphorylated (manufacturer’s instructions, Invitrogen, Eugene, OR). This sug-
gests other kinds of PTM, for example glycosylation (Fig 6C).
Fig 3. %Vol of spots ID288, ID289 and ID469 in individual patients.Graphical representation of %Vol
values of spots ID288, ID289 and ID469 showing the widest inter-individual range in the population studied
(0,00–0,44; 0,06–0,33; 0,01–0,54 respectively). The %Vol values are expressed as the mean of at least three
replicates ± SD.
doi:10.1371/journal.pone.0129291.g003
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Discussion
MS is a neurological disease characterized by a complex pathogenesis and an unpredictable
prognosis. Over the years, it has become evident that the processes concerning the clinical
manifestations of MS such as inflammation, demyelination, axonal damage and repair mecha-
nisms, are not equally observed in all patients but can electively predominate in individual sub-
jects. This implies that there are many expressions of the disease and various types of response
to treatment [1].
Fig 4. Two spot-based cluster analysis (spot ID 288 e ID 289). (A) Graph showing the results of linear discriminant analysis based on the two linear
functions (f1 = 33.813*(%Vol spot ID288) + 48.942*(%Vol spot ID289)– 7.155; f2 = 103.508*(%Vol spot ID288) + 42.871*(%Vol spot ID289)– 15.248)
allowing optimal separation of clusters G and Z based on the measured variables (spot ID 288 and ID 289). The mathematical function separating the two
groups is also reported. (B) Hierarchical cluster analysis based on the %Vol values of spots ID288 and ID289 identify two clusters, G and Z, and one outlier
MS48. The clinical classification of the patients included in the study is indicated alongside the sample number: L = MS patients with a mildly aggressive
disease; LB = MS patients with a benign form of the disease; M = MS patients with a moderately aggressive disease; H = MS patients with a highly
aggressive disease; PP = MS patients with a primary progressive form of the disease; NA: patients lost to follow-up; no MS: patient with an unconfirmed
diagnosis of MS. (C) Column bar graph shows%Vol values of spots ID288 and ID289 in clusters Z and G: values are expressed as the mean of three
technical replicates ± SD (bars). * P<0.05, *** P<0.001 (MannWhitney’s Test). (D) Spearman statistical analysis shows a significant inverse correlation
between spots ID288 and ID289%Vol values for each subject (r = -0.49, p = 0.015).
doi:10.1371/journal.pone.0129291.g004
Table 5. Patient categorization according to two and three spot-based clustering and disease aggressiveness.
Patients Cluster (288, 289) Cluster (288, 289, 469) Clinical classification 2 years fu Clinical classification 5 years fu
MS25 Z OUT PP PP
MS26 Z B1 M death
MS27 Z B1 H H
MS29 Z B1 H H
MS44 Z B1 H H
MS47 Z B1 H H
MS28 G D1 M H
MS35 Z B1 M M
MS30 Z D1 M M
MS31 G D1 L M
MS32 Z D1 M M
MS33 G D1 M M
MS37 G D1 M M
MS38 G D1 M M
MS42 G D1 M M
MS43 G D1 M M
MS46 G D1 M M
MS34 G D1 L L
MS36 G D1 L L
MS45 G D1 L L
MS39 G C1 L (B) L (B)
MS40 G C1 L (B) L (B)
MS41 G C1 lost lost
MS48 OUT C1 no MS no MS
H (high) = highly aggressive disease form, second-line approved therapies (natalizumab or fingolimod); M (moderate) = moderately aggressive disease,
first-line approved therapies (interferon beta or glatiramer acetate); L (low) = scarcely aggressive or L (B) “benign” disease, no therapy. The “benign” forms
of MS are characterized by no disease progression/activity without specific disease-modifying treatments for more than 10 years. Patients are ranked
based on the clinical category to 5 years follow-up (fu). Fu = follow-up; OUT = outlier; lost = patients lost at follow-up.
doi:10.1371/journal.pone.0129291.t005
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Most MS lesions are typically located in the periventricular white matter of the brain and in
superficial areas of the spinal cord, which share anatomical proximity to the liquoral space. As
brain biopsies are generally unavailable, the CSF represents a unique repository of pathological
information, since it is secreted from CNS structures and contains peptides, proteolytic frag-
ments and antibodies, which may reflect the presence and progression of the disease [22].
To date, despite extensive literature on CSF biomarkers in MS, only qualitative and quanti-
tative biochemical methods are used in clinical practice for assessing the intrathecal production
of immunoglobulins [23].
It is essential to find prognostic biomarkers in the CSF in order to enable researchers and
clinicians to prescribe appropriate and personalized therapies.
Innovative ‘omics’ techniques are currently available for carrying out research on biomark-
ers at various levels of expression (genomic, transcriptomic, proteomic and metabolomic). In
particular, proteomic technologies such as immunoblotting, isoelectric focusing, 2-DE and
mass spectrometry, have proved to be useful tools for identifying the biomolecules required for
categorizing the various subtypes of diseases.
Up to now, CSF proteomic data generated by various laboratories are still extremely variable
and have not yet been validated [24]. This is partly due to the intrinsic variability of the tech-
nique, but it is also influenced by pre-analytical factors (i.e. sample collection, patient heteroge-
neity, poor experimental design, blood contamination, processing and storage artifacts).
Moreover, considering the limited amounts of CSF collected, most proteomic studies were
performed on pooled CSF samples. Although the pooling strategy may minimize potential
inter-individual differences of CSF protein content that are not related to the disease, CSF pool-
ing may hinder the detection of markers of the various subtypes of the disease with potentially
different pathological mechanisms [10]. Therefore, it is preferable to analyse individual CSF.
In this study we followed precise inclusion criteria for selecting the patients and CSF sam-
ples and respected standardized procedures during sampling, handling and storage phases and
Table 6. Descriptive statistical analysis of H, M, L patient distribution in G, Z, B1, C1, D1 clusters at 2
and 5 years follow-up.
2 YEARS FU Clinical classification
H L M
2 cluster identification
G 0% 83.33% 72.73%
Z 100% 16.67% 27.27%
3 cluster identification
B1 100% 16.67% 9.09%
C1 0% 33.33% 0%
D1 0% 50% 90.91%
5 YEARS FU
H L M
2 cluster identification
G 20% 100% 70%
Z 80% 0% 30%
3 cluster identification
B1 80% 0% 10%
C1 0% 40% 0%
D1 20% 60% 90%
FU = follow-up.
doi:10.1371/journal.pone.0129291.t006
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Fig 5. Three spot-based cluster analysis (ID 288, ID 289 and ID469). (A) Dendrogram of the hierarchical cluster analysis based on the %Vol values of
spots ID288, ID289 (DBP isoforms) and ID469 (ApoE), showing wider inter-individual range of %Vol values in the differently expressed spots. (B) Column bar
graph showing %Vol values of spots ID 288, ID 289, ID 469 in clusters B1, C1 and D1. Values are expressed as the mean of the technical replicates ± SD
(bars).
doi:10.1371/journal.pone.0129291.g005
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during 2-DE analyses. Thanks to the availability of a large amount of CSF obtained from each
patient by means of an innovative LP protocol [14], we were able to perform 2-DE analysis on
individual CSF samples with an adequate number of replicates (at least three with less than
30% variability). All 2-DE analyses were carried out by the same operators, under standardized
conditions over a short period of time.
A control group was not included in the study since the goal was to identify CSF biological
markers that are able to predict the prognosis of MS. Moreover, it is difficult to obtain CSF
from healthy controls and the criteria for classifying the various control subsets have only re-
cently been established [5]. Interestingly, the only patient diagnosed with somatophorm disor-
der was classified as an outlier in the clusterization concerning DBP isoforms (Fig 4B) and she
was included in the subset of patients suffering from less aggressive MS when ApoE and DBP
isoforms were considered together (Fig 5A, Table 5).
EDSS and relapse rates are the traditional clinical parameters used for measuring the pro-
gression and aggressiveness of MS in natural history. However, the availability of DMTs, in
particular NAT and FIN, have greatly reduced the relapse rate and disability progression [25,
26] of RRMS forms, making these parameters a measure of responsiveness to the drugs and
not of disease aggressiveness. The aim of this study was to explore markers of disease aggres-
siveness defined by the type of DMT proposed or prescribed to the patients at the end of the
follow-up.
The hierarchical clustering analysis of the 239 spots obtained with the 2-DE analysis, a non-
hypothesis driven approach, initially selected 12 spots (Fig 2B and Table 4).
Further cluster analysis of the 12 spots showed that three of them, two isoforms of DBP
(spot ID288 and ID289) and an isoform of ApoE (spot ID469), were the key proteins responsi-
ble for driving the clustering. The correlation between the subsets of patients obtained by
means of the cluster analysis and the subsets of patients classified according to the degree of
disease aggressiveness (H, M and L) showed that this approach can help to predict the clinical
course. In particular, patient stratification obtained with the cluster analysis according to the
Table 7. Probability of being classified as H, M or L by three spot-based (DBP isoforms and ApoE) and two spot-based (DBP isoforms) clustering
at 2 and 5 years follow-up.
p-value 2 YEARS FU Clinical classification
2 cluster identification H L M
0.016 G 0% 38.28% 61.72%
Z 50.06% 12.77% 37.17%
3 cluster identification
0.001 B1 66.56% 16.97% 16.47%
C1 0% 100% 0%
D1 0% 23.06% 76.94%
5 YEARS FU
2 cluster identification H L M
0.027 G 7.69% 38.46% 53.84%
Z 57.14% 0% 42.86%
3 cluster identification
0.002 B1 80% 0% 20%
C1 0% 100% 0%
D1 7.69% 23.08% 69.23%
FU = follow-up.
doi:10.1371/journal.pone.0129291.t007
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two isoforms of DBP identified patients who were likely to develop a highly aggressive form (H
category) of MS in the following 5 years (cluster Z, Fig 4B and Table 5). Adding ApoE to the
cluster analysis improved the categorization of patients (Fig 5A and Table 5). In fact, the three
spot-based clustering approach correctly grouped 4 out of the 5 patients with aggressive MS in
cluster B1 at the 5-year follow-up and identified 9 out of the 10 patients suffering from a mod-
erate form in the cluster D1. By clustering with DBP isoforms and ApoE, it was also able to
identify a small group of patients (cluster C1) characterized by a”benign” form (L-B category)
or with no disease in one case (MS48). As shown in Table 7, the probability of being classified
as H, M or L differs significantly among the clusters obtained with both approaches (two spot-
and three spot-based clusterization). The three spot-based analysis better correlated with the
classification based on the clinical course at the five-year follow-up. In fact, there is an 80%
probability that the disease will evolve into aggressive forms for the patients in cluster B1, while
there is a 100% probability that the disease will remain “benign” for the patients in cluster C1
(Table 7).
Further investigation revealed that the amounts of the two DBP isoforms (spot ID288 and
ID289) did not change concurrently but they showed an inverse correlation: by describing the
combination of the %Vol of these two spots by means of two linear functions, it is possible to
separate highly aggressive MS forms from moderate/low MS forms.
Besides transporting vitamin D metabolites [27], DBP carries out several important func-
tions, including actin sequestration and a range of less-defined roles in modulating immune
and inflammatory responses. Several studies suggest a role of DBP in MS [6, 7, 8, 12, 28, 29].
Considering the association between low vitamin D status and MS [30], many have searched
for a possible association between the concentration of DBP in CSF or serum and MS with
equivocal results [6, 12, 24, 31, 32, 33]. In our study, the inverse correlation of the two DBP iso-
forms suggested the relative prevalence of one of the isoforms rather than the total DBP ac-
counts for the patient categorization. This suggests that a PTMmay be related to the degree of
aggressiveness and therefore have a prognostic meaning.
DBP may undergo various kinds of PTM, among which phosphorylation and glycosylation.
Erikson et al. [21] proposed the level of phosphorylated DBP in CSF as a promising tool for dis-
tinguishing relapsing-remitting MS from secondary progressive MS forms and from other neu-
rological diseases. Our preliminary phospho-proteomic experiments did not confirm a
difference in DBP phosphorylation status (Fig 6C).
Glycosylation is another PTM which may explain the presence of two DBP isoforms in
2-DE gels. In fact, DBP occurs in several isoforms with various levels of glycosylation [34, 35,
36]. Different levels of glycosylated (sialylated) isoforms of DBP with predictive clinical value
had already been demonstrated in a 2-DE study carried out on juvenile idiopathic arthritis
[37], a poorly understood group of chronic autoimmune diseases.
The degree of glycosylation seems to regulate the inflammatory and immunological activi-
ties of DBP. Glycosylation of DBP through the combined action of a betagalactosidase and a
sialidase engenders the Gc macrophage activating factor (GcMAF), the most potent activator
of macrophages with an important role in immune system regulation and anti-angiogenetic ac-
tivity in cancer patients [34, 38]. The two spots found in this study might differ for their glyco-
sylation status. As the glycosylation of DBP isoforms affects the binding affinity for vitamin D
Fig 6. Validation of 2-DE results by western blotting and phospho-proteomic analyses. (A) Representative 2-DE western blotting of DBP and ApoE
obtained from pooled CSF samples from patients included in clusters B1 and C1. Arrows point to DBP isoforms (spots ID288 and ID289) in the upper panel,
and to ApoE in the lower one. (B) Column bar graph showing optical density (OD) values of the spots visualized by 2-DE immunoblotting (ID288, ID289 and
ID469). Values are expressed as the mean of three technical replicates ± SD (bars). (C) ProQ Diamond- and Sypro-stained 2-DE gels obtained from pooled
CSF samples from patients included in clusters B1 with that of C1.
doi:10.1371/journal.pone.0129291.g006
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metabolites and consequently their circulating levels [39, 40, 41], we can speculate that the de-
gree of DBP glycosylation or the activity of glycosylating/deglycosylating enzymes may have a
prognostic and diagnostic value in MS. Glycoproteomic experiments aimed at verifying this
hypothesis are in progress in our laboratories.
The second protein which contributed to the identification of the clinically relevant sub-
types is ApoE (spot ID469). Many researchers have reported the association between ApoE ε4
allele and the increased risk of MS, showing that ε4 predisposes to faster progression [42]. The
2-DE analysis did not enable us to distinguish among the different ApoE allelic forms. Howev-
er, the patients included in cluster C1, characterized by a benign course, had lower levels of
ApoE than those in cluster B1, who developed highly aggressive forms.
Although there are some limitations in the study (i.e. small number of patients, the use of
semi-quantitative method), the non-hypothesis driven approach combined with accurate pre-
analitical procedures, standardized laboratory methods and 5-year follow-ups of women with
suspected MS, enabled us to identify potential biomarkers of MS prognosis. In addition, these
biomarkers could also have a biological role in the pathogenesis of the disease. Obviously, these
findings require wider validation studies to be carried out on a larger population in
various laboratories.
Conclusions and Perspectives
This study proposes a novel biomolecular tool consisting of two isoforms of DBP and ApoE
which may be useful for monitoring the progression of the disease. If validated on an larger in-
dependent population of retrospectively selected CSF samples, this study could positively effect
the treatment, prognosis and understanding of MS and assist the clinician(s) in the daily man-
agement of MS patients. Future activities will involve the analysis of a control group including
other neurological patients in order to confirm the specificity of the results for MS.
Further studies on the glycosylation status of DBP and the activity of the enzymes involved
in glycosylation/deglycosylation may shed light on the pathogenesis of the disease and help de-
termine new goals for treatment.
The use of DBP as a prognostic tool in MS has been patented (EP2664923).
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